Lucigen/TargetAmp™1轮生物素aRNA扩增试剂盒105/TAB1R80524/24反应

价格
¥18320.00
货号:TAB1R80524
浏览量:127
品牌:Lucigen
服务
全国联保
正品保证
正规发票
签订合同
商品描述

Optimizedforhighyield,highqualitybiotin-aRNA

  • Formerly from EpicentreHighlyreproducIBLeamplification,labeling,andmicroarrayresults.
  • MultipleRNAsamplescanbeeasilyamplifiedandlabeledsimultaneously.
  • LinearRNAamplificationprocesspreservesthetranscriptprofileofthesample.
  • Simple,single-tube,6-hourprocedure.Preparebiotin-aRNAandbeginhybridizationthesameday.
  • Biotin-aRNAproducedbythekitdetectsmoretranscripts(genes)thancompetitorkitsandshowedhighcorrelationwithMAQCTaqMan®data(Fig.1).

Applications

TheTargetAmp™1-RoundBiotin-aRNAAmplificationKit105*producesmicrogramamountsofbiotin-antisenseRNA(biotin-aRNA,alsocalledbiotin-cRNA)fromaslittleas25ngoftotalcellularRNA.Thekitprovidesallreagentsforthepreparationofbiotin-aRNA(exceptreversetranscriptaseandRNApurificationcolumns)andusesanimprovedEberwine-typelinearamplificationmethod1toachieveatleast5,000-foldamplificationofthepoly(A)RNApresentinatotalcellularRNAsample.Theentireprocedurecanbecompletedin1day.

Table1.ATargetAmp™Kit105reactionproduceshighyieldsofbiotin-aRNAfromaslittleas25ngofinputtotalRNA.Resultsrepresenttheaverageofmultipleexperiments.

AmountofInputHeLaTotalRNABiotin-aRNAYieldfromHeLaTotalRNAa
25ng4.1µg
100ng13.7µg
500ng64.9µg

a.Approximately2%ofHeLatotalRNAispoly(A)RNA.

Figure1.CorrelationofexpressionratiosobtainedfromqPCRandfrommicroarrayshybridizedtoaRNApreparedwiththeTargetAmp™105kit.Xaxis,log2expressionratiosdeterminedfromHumanGenomeU133Plus2.0Arrays(Affymetrix)hybridizedtotargetspreparedbytheTargetAmp105kit;Yaxis,log2expressionratiosdeterminedbytheMAQC,usingTaqMan®assays.Thehighcorrelationobtained(r=0.936)indicatestheexcellentfidelityoftheamplificationprocess.

References

  1. VanGelder,R.N.etal.(1990)Proc.Natl.Acad.Sci.USA87,1663.

*TargetAmp™aRNAAmplificationProductsarecoveredbyintellectualpropertylicensedtoEpicentreTechnologiesCorporationfromJohnson&JohnsonPharmaceuticalResearch&Development,L.L.C.,andbyintellectualpropertysublicensedtoEpicentreTechnologiesCorporationfromIncyteCorporation.

Forresearchuseonly.Someapplicationsinwhichthisproductmaybeusedmaybecoveredbypatentsorpatentapplicationsapplicableincertaincountries.Becausepurchaseofthisproductdoesnotincludealicensetoperformanypatentedapplication,usersofthisproductmayberequiredtoobtainalicense,dependingupontheparticularapplicationandcountryinwhichtheproductisused.

ORDERINFORMATION

ThesekitswereoptimizedusingSuperScript™IIIreversetranscriptase(Invitrogen),whichisnotincludedinthekits.Contents:TargetAmp™T7-Oligo(dT)PrimerA,TargetAmp™ReverseTranscriptionPreMix,TargetAmp™DNAPolymerasePreMixI,TargetAmp™DNAPolymerase,TargetAmp™T7RNAPolymerase,TargetAmp™T7TranscriptionBuffer,TargetAmp™NTPPreMix,TargetAmp™UTP/Biotin-UTP,RNase-FreeDNaseI,DTT,HeLaTotalRNAControl,RNase-FreeWater. 美国Lucigen公司,自1998年成立至今,一直致力于生命科学领域相关科研产品的研究与开发,在分子生物学领域处于领导性地位。Lucigen公司主要开发各类用于基因克隆的试剂盒及相关产品,包括:CloneSmart®平端克隆试剂盒、BigEasy®线性克隆系统、pEZSeq™平端克隆试剂盒、ClonePlex™ AK文库构建试剂盒、DNA Terminator ®末端修复试剂盒、EconoTaq® DNA聚合酶及E.cloni感受态细胞等。Lucigen公司凭借其独到的产品技术,过硬的产品质量,良好的产品服务赢得了全球广大用户的信赖。